SEC Form 4 · accession 0001019056-18-000463
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marvin L White
Officer — President and CEO · Director
Period of report
Mar 19, 2018
Accepted (ET)
Mar 21, 2018 · 11:57 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 19, 2018 | S | 100,000 | $2.93 | A | 166,332 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $2.93 is reflective of the weighted average sale price. The prices for the transactions reported on this line range from $2.865 to $3.020, inclusive. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.